相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
Hetakshi Kurani et al.
CLINICAL CANCER RESEARCH (2022)
Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
Pavlina Spiliopoulou et al.
MOLECULAR CANCER THERAPEUTICS (2022)
Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma
Peiwei Chai et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2022)
Platinum-based drugs for cancer therapy and anti-tumor strategies
Chunyu Zhang et al.
THERANOSTICS (2022)
DOT1L activity in leukemia cells requires interaction with ubiquitylated H2B that promotes productive nucleosome binding
Cathy J. Spangler et al.
CELL REPORTS (2022)
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors A Review
Ananthan Sadagopan et al.
JAMA ONCOLOGY (2022)
Lysine methyltransferase inhibitors: where we are now
Alessandra Feoli et al.
RSC CHEMICAL BIOLOGY (2022)
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias
Yan Yi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies
Ying Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
Marjorie G. Zauderer et al.
LANCET ONCOLOGY (2022)
EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis
Jun Wang et al.
NATURE CELL BIOLOGY (2022)
DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway
Danfeng Sun et al.
ONCOIMMUNOLOGY (2022)
Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer
Yimin Li et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Histone lysine methyltransferase SET8 is a novel therapeutic target for cancer treatment
Chao Yang et al.
DRUG DISCOVERY TODAY (2021)
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease
Kamakoti P. Bhat et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Regulation of the Dot1 histone H3K79 methyltransferase by histone H4K16 acetylation
Marco Igor Valencia-Sanchez et al.
SCIENCE (2021)
Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death
Vicente Fresquet et al.
CANCER DISCOVERY (2021)
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma
Gregory M. Kelly et al.
CLINICAL CANCER RESEARCH (2021)
Targeting of histone methyltransferase DOT1L plays a dual role in chemosensitization of retinoblastoma cells and enhances the efficacy of chemotherapy
Yu Mao et al.
CELL DEATH & DISEASE (2021)
Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling
Qianxi Yang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins
Xin Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity
Gabriel K. Griffin et al.
NATURE (2021)
Towards precision medicine for AML
Hartmut Dohner et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward
Amila K. Nanayakkara et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan
Koji Izutsu et al.
CANCER SCIENCE (2021)
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1) an-label, 2 trial
Johann S. de Bono et al.
LANCET ONCOLOGY (2021)
A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies
Zhiwei Liu et al.
MOLECULAR CELL (2021)
Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma
Laurie Herviou et al.
CLINICAL EPIGENETICS (2021)
Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia
William F. Richter et al.
ELIFE (2021)
Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis
Suresh Chava et al.
ONCOGENESIS (2021)
ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression
Geyan Wu et al.
EBIOMEDICINE (2021)
The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma
Xing Wang et al.
CANCERS (2021)
Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma
Johanna A. Seier et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth
Fangrui Wu et al.
THERANOSTICS (2021)
Advancing targeted protein degradation for cancer therapy
Brandon Dale et al.
NATURE REVIEWS CANCER (2021)
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential
Dimitrios Strepkos et al.
CANCER RESEARCH (2021)
Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer
Liye Zhou et al.
CLINICAL CANCER RESEARCH (2020)
Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise
Daphne Morel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Sona Vodenkova et al.
PHARMACOLOGY & THERAPEUTICS (2020)
A LYSA Phase lb Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features
Clementine Sarkozy et al.
CLINICAL CANCER RESEARCH (2020)
Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAFV600E by synergistically decreasing global trimethylation of H3K27
Hao Fu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Verification of EZH2 as a druggable target in metastatic uveal melanoma
Bei Jin et al.
MOLECULAR CANCER (2020)
Network Inference Analysis Identifies SETDB1 as a Key Regulator for Reverting Colorectal Cancer Cells into Differentiated Normal-Like Cells
Soobeom Lee et al.
MOLECULAR CANCER RESEARCH (2020)
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response
Wendy Beguelin et al.
CANCER CELL (2020)
H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade
Friederike Hoffmann et al.
CLINICAL EPIGENETICS (2020)
SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways
Huairui Yuan et al.
CANCER CELL (2020)
EZH2: a novel target for cancer treatment
Ran Duan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
E2F7-EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression
Rui Yang et al.
BRITISH JOURNAL OF CANCER (2020)
The Contribution of Epigenetics to Cancer Immunotherapy
Lorea Villanueva et al.
TRENDS IN IMMUNOLOGY (2020)
Epigenetic modulator inhibition overcomes temozolomide chemoresistance and antagonizes tumor recurrence of glioblastoma
Byoung-San Moon et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Mrinal Gounder et al.
LANCET ONCOLOGY (2020)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser et al.
LANCET ONCOLOGY (2020)
DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation
Kaixiang Cao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
Hye-Jung Kim et al.
TRENDS IN IMMUNOLOGY (2020)
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer
R. Vatapalli et al.
NATURE COMMUNICATIONS (2020)
Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma
Sungryul Park et al.
CANCERS (2020)
EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
Hao Gong et al.
BMC CANCER (2020)
Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer
Chuntao Quan et al.
CANCER LETTERS (2020)
Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer
Xiao Tan et al.
CELL DEATH & DISEASE (2020)
Deficiency of G9a Inhibits Cell Proliferation and Activates Autophagy via Transcriptionally Regulating c-Myc Expression in Glioblastoma
Xiao Xue Ke et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer
Miku Wada et al.
BIOMOLECULES (2020)
miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer
Jing Sun et al.
ONCOGENE (2019)
Mechanism of Cross-talk between H2B Ubiquitination and H3 Methylation by Dot1L
Evan J. Worden et al.
CELL (2019)
Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer
Swathi Ramakrishnan et al.
CELL DEATH AND DIFFERENTIATION (2019)
EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis
Yu Zhao et al.
EMBO JOURNAL (2019)
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
Daisuke Ennishi et al.
CANCER DISCOVERY (2019)
Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells
Giovanni Nassa et al.
SCIENCE ADVANCES (2019)
BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype
Ielizaveta Gorodetska et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
SETD2 regulates the maternal epigenome, genomic imprinting and embryonic development
Qianhua Xu et al.
NATURE GENETICS (2019)
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Cristina Segovia et al.
NATURE MEDICINE (2019)
An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis
Harvey W. Smith et al.
NATURE COMMUNICATIONS (2019)
LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC
Xinyin Liu et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew Lunning et al.
BLOOD (2019)
Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents
Hao Cao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy
Alison Hirukawa et al.
CELL REPORTS (2019)
Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas
Makoto Yamagishi et al.
CELL REPORTS (2019)
G9a promotes cell proliferation and suppresses autophagy in gastric cancer by directly activating mTOR
Chao Yin et al.
FASEB JOURNAL (2019)
Long Non-coding RNA LINC-PINT Suppresses Cell Proliferation and Migration of Melanoma via Recruiting EZH2
Yangfan Xu et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
Pei-Pei Kung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia
J. Bu et al.
LEUKEMIA (2018)
Epigenetics of malignant melanoma
Bruce Moran et al.
SEMINARS IN CANCER BIOLOGY (2018)
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
Eytan M. Stein et al.
BLOOD (2018)
Chemical and Biochemical Perspectives of Protein Lysine Methylation
Minkui Luo
CHEMICAL REVIEWS (2018)
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoine Italiano et al.
LANCET ONCOLOGY (2018)
Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway
Lihui Wang et al.
CELL DEATH & DISEASE (2018)
The protective role of DOT1L in UV-induced melanomagenesis
Bo Zhu et al.
NATURE COMMUNICATIONS (2018)
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity
David Wang et al.
CELL REPORTS (2018)
Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells
Minmin Liu et al.
CANCER RESEARCH (2018)
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
Xun Huang et al.
CELL (2018)
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy
Sangeeta Goswami et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells
Youping Yang et al.
ONCOTARGETS AND THERAPY (2018)
Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator
Jung Kim et al.
CELL REPORTS (2018)
Inhibitors of Protein Methyltransferases and Demethylases
H. Umit Kaniskan et al.
CHEMICAL REVIEWS (2018)
DOT1L and H3K79 Methylation in Transcription and Genomic Stability
Katherine Wood et al.
BIOMOLECULES (2018)
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia
C. Dafflon et al.
LEUKEMIA (2017)
Targeting the histone methyltransferase G9a activates imprinted genes and improves survival of a mouse model of Prader-Willi syndrome
Yuna Kim et al.
NATURE MEDICINE (2017)
Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma
Yanxiao Wang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate-Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma
Chia-Wen Liu et al.
MOLECULAR CANCER THERAPEUTICS (2017)
The winding path of protein methylation research: milestones and new frontiers
Jernej Murn et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Daniel Zingg et al.
CELL REPORTS (2017)
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming
Remi Adelaiye-Ogala et al.
CANCER RESEARCH (2017)
Monomethyltransferase SETD8 regulates breast cancer metabolism via stabilizing hypoxia-inducible factor 1 α
Run Huang et al.
CANCER LETTERS (2017)
Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma
Veronica Veschi et al.
CANCER CELL (2017)
Up-Regulation of Histone Methyltransferase SETDB1 by Multiple Mechanisms in Hepatocellular Carcinoma Promotes Cancer Metastasis
Chun-Ming Wong et al.
HEPATOLOGY (2016)
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
Takafumi Shimizu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
Zizhen Feng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
Rishi G. Vaswani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer
Sheng-Mou Hsiao et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer
Jian Geng et al.
CANCER LETTERS (2015)
Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma
Mehnaz Khan et al.
LABORATORY INVESTIGATION (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia
Chun-Wei Chen et al.
NATURE MEDICINE (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2
Lianying Jiao et al.
SCIENCE (2015)
Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression
Nienke A. de Vries et al.
CELL REPORTS (2015)
Long non-coding RNA ROR decoys gene-specific histone methylation to promote tumorigenesis
Jiayan Fan et al.
GENOME BIOLOGY (2015)
EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells
Bryson W. Katona et al.
CANCER BIOLOGY & THERAPY (2014)
AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes
Aniruddha J. Deshpande et al.
CANCER CELL (2014)
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis
Kuo-Tai Hua et al.
MOLECULAR CANCER (2014)
DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells
Christine R. Klaus et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells
Ju-Kyung Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Scott R. Daigle et al.
BLOOD (2013)
Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP
Feng Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer
Chenfang Dong et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Histone methylation: a dynamic mark in health, disease and inheritance
Eric L. Greer et al.
NATURE REVIEWS GENETICS (2012)
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Kexin Xu et al.
SCIENCE (2012)
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors
Wenyu Yu et al.
NATURE COMMUNICATIONS (2012)
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Scott R. Daigle et al.
CANCER CELL (2011)
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Kathrin M. Bernt et al.
CANCER CELL (2011)
Regulation of chromatin by histone modifications
Andrew J. Bannister et al.
CELL RESEARCH (2011)
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Vicki Leigh Keedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers
Shuet Theng Lee et al.
MOLECULAR CELL (2011)
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
Masoud Vedadi et al.
NATURE CHEMICAL BIOLOGY (2011)
Histone H4 Lys 20 monomethylation by histone methylase SET8 mediates Wnt target gene activation
Zhenfei Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
Christopher J. Sneeringer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
Chemically ubiquitylated histone H2B stimulates hDot1L-mediated intranucleosomal methylation
Robert K. McGinty et al.
NATURE (2008)
MLL translocations, histone modifications and leukaemia stem-cell development
Andrei V. Krivtsov et al.
NATURE REVIEWS CANCER (2007)
Modulation of p53 function by SET8-mediated methylation at lysine 382
Xiaobing Shi et al.
MOLECULAR CELL (2007)
High-resolution profiling of histone methylations in the human genome
Artern Barski et al.
CELL (2007)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase
Stefan Kubicek et al.
MOLECULAR CELL (2007)
The diverse functions of histone lysine methylation
C Martin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
hDOT1L links histone methylation to leukemogenesis
Y Okada et al.
CELL (2005)
Regulation of chromatin structure by site-specific histone H3 methyltransferases
S Rea et al.
NATURE (2000)
分享论文
